ROIVNasdaqPharmaceutical PreparationsFiscal year ends March 31

Roivant Sciences Ltd.

Financials through Q1 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026

$34.70+1.17 (+3.49%)

Close on Oct 19, 2026

Market cap: $25.01B
P/E (TTM): –
Dividend yield: –

Roivant Sciences Ltd. income statement

Millions of USD, except per-share data. Shares in millions.

Line item	FY 2025 2026-03-31	FY 2024 2025-03-31	FY 2023 2024-03-31	FY 2022 2023-03-31	FY 2021 2022-03-31	FY 2020 2021-03-31
Revenue	8.26	29	33	32	55	24
Research & Development	682	550	440	454	483	237
Selling, General & Admin	–	–	687	601	775	–
General & Administrative	610	591	416	383	775	260
Operating Expenses	1,294	1,143	884	938	1,407	1,095
Operating Income	-515	-1,003	4,497	-907	-1,352	-1,071
Interest Expense	–	–	35	28	7.04	2.81
Interest & Investment Income	178	258	146	–	0.37	1.42
Income from Equity Investments	–	–	–	–	0	-3.75
Other Non-Operating Income	4.01	-11	-14	-0.49	3.24	-8.70
Asset Impairment Charges	17	–	–	–	–	–
Gain (Loss) on Investments	105	55	-48	-21	-87	96
Gain (Loss) on Sale of Assets	–	–	5,348	0	–	–
Pretax Income	-265	-682	4,568	-885	-924	-899
Income Tax Expense	133	48	22	4.08	0.37	1.69
Income from Continuing Operations	-300	-545	4,663	-784	-845	–
Income from Discontinued Operations	0	373	-315	-226	0	–
Net Income incl. Noncontrolling Interests	-398	-357	4,231	-1,115	-924	-900
Minority Interest in Earnings	-98	-185	-118	-106	-79	-91
Net Income	-300	-172	4,349	-1,009	-845	-809
Net Income to Common	-300	-172	4,349	–	–	–
EPS (Basic)(per share)	-0.43	-0.24	5.55	-1.42	-1.26	-1.28
EPS (Diluted)(per share)	-0.54	-0.24	5.23	-1.42	-1.26	-1.28
Shares Outstanding (Basic, Weighted)(shares)	694	725	783	713	670	630
Shares Outstanding (Diluted, Weighted)(shares)	694	725	831	713	670	630
EBITDA	-512	-989	4,519	-888	-1,346	–

Italic numbers are calculated by StockData (for example Q4 = full year − nine months). Per-share data and share counts are adjusted for stock splits. Hover a number for its source; click it to open the filing on SEC.gov. Click a row to chart it.

Ratios

Latest available, balances at Jun 30, 2026

Profitability, TTM

Gross margin: –
Operating margin: -7914.8%
Net margin: -3535.0%
Return on equity, FY2025: -6.5%

Financial strength

Current ratio: 16.72
Debt to equity: –
Debt to assets: –
Cash to current liabilities: 440.2%

Valuation

P/E ratio: –
Price to sales: 3320.63
Price to book: 5.91
Dividend yield: –